SELLAS Life Sciences Group Balance Sheet Health
Financial Health criteria checks 4/6
SELLAS Life Sciences Group has a total shareholder equity of $9.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.4M and $14.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$18.42m |
| Equity | US$9.68m |
| Total liabilities | US$14.75m |
| Total assets | US$24.43m |
Recent financial health updates
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Jul 13
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Sep 20We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully
Mar 08Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?
Nov 23Recent updates
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Jul 13SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Sep 20SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study
Aug 09We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully
Mar 08Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?
Nov 23Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth
Jul 19SELLAS Life Sciences updates on at-the-market offering
Jun 02SELLAS Life Sciences jumps 43% after Reddit mentions
Feb 03Sellas' galinpepimut-S combo shows promising action in early-stage solid tumor studies
Dec 21Sellas Life Sciences strengthens balance sheet with addition of $30.5M
Dec 17Sellas Life Sciences prices $16.2M direct offering
Dec 14Nelipepimut-S data from breast cancer study fails to lift SELLAS Life Sciences
Dec 11SELLAS and 3D Medicines in exclusive license agreement for development and commercialization of GPS and GPS+ in Greater China
Dec 07SELLAS Life Sciences EPS misses by $0.26
Nov 13Financial Position Analysis
Short Term Liabilities: SLS's short term assets ($21.5M) exceed its short term liabilities ($14.4M).
Long Term Liabilities: SLS's short term assets ($21.5M) exceed its long term liabilities ($313.0K).
Debt to Equity History and Analysis
Debt Level: SLS is debt free.
Reducing Debt: SLS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SLS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.3% each year